Eradication Therapy in Helicobacter pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis
- 1 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 99 (9) , 1833-1855
Abstract
We conducted a systematic review and economic analysis to ascertain the efficacy of eradication therapy in the treatment of H. pylori positive peptic ulcer disease. Comprehensive search of electronic databases, bibliographies of retrieved articles, contact with pharmaceutical companies, and experts in the field to identify published and unpublished literature from 1966 to the present. The data were incorporated into a Monte Carlo simulation Markov model that incorporated all the uncertainty in the estimates to evaluate cost-effectiveness. Fifty-two trials were included in the final metaanalysis. In duodenal ulcer healing, H. pylori eradication therapy was superior to ulcer healing drug (relative risk (RR) of ulcer persisting = 0.66; 95% confidence interval (CI) = 0.58 to 0.76) and no treatment (RR = 0.37; 95% CI 0.26 to 0.53). In gastric ulcer healing, H. pylori eradication therapy was not statistically superior to ulcer healing drug (RR = 1.32; 95% CI = 0.92 to 1.90). In preventing duodenal ulcer recurrence, H. pylori eradication therapy was not statistically superior to maintenance therapy with ulcer healing drug (RR of ulcer recurring = 0.73; 95% CI = 0.42 to 1.25), but was superior to no treatment (RR = 0.19; 95% CI = 0.15 to 0.26). In preventing gastric ulcer recurrence, H. pylori eradication was superior to no treatment (RR = 0.31; 95% CI 0.19 to 0.48). The Markov model suggested H. pylori eradication is cost-effective for duodenal ulcer over 1 year and gastric ulcer over 2 years with over 95% confidence despite the uncertainty in the data. H. pylori eradication therapy reduces the recurrence of peptic ulcer disease and is cost-effective.Keywords
This publication has 59 references indexed in Scilit:
- An Alternative Non‐Macrolide, Non‐Imidazole Treatment Regimen for Curing Helicobacter pylori and Duodenal Ulcers: Ranitidine Bismuth Citrate Plus AmoxicillinHelicobacter, 1998
- Double-Blind Trial of Omeprazole and Amoxicillin in the Cure ofHelicobacter pyloriInfection in Gastric Ulcer PatientsScandinavian Journal of Gastroenterology, 1998
- Ranitidine Versus Colloidal Bismuth Subcitrate in Combination with Amoxicillin and Metronidazole for EradicatingHelicobacter pyloriin Patients with Duodenal UlcerClinical Infectious Diseases, 1997
- Ranitidine Bismuth Citrate with Clarithromycin for the Eradication ofHelicobacter pyloriand for Ulcer HealingHelicobacter, 1997
- Double‐Blind, Multicenter Evaluation of Lansoprazole and Amoxicillin Dual Therapy for the Cure of Helicobacter pylori InfectionHelicobacter, 1996
- Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patientsAlimentary Pharmacology & Therapeutics, 1996
- Double‐blind, Multicenter, Placebo‐Controlled Evaluation Of Clarithromycin And Omeprazole For Helicobacter Pylori‐Associated Duodenal UlcerHelicobacter, 1996
- Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double‐blind, multi‐centre trial of omeprazole with or without clarithromycinAlimentary Pharmacology & Therapeutics, 1995
- Combination Therapies with a Proton Pump Inhibitor for Helicobacter pylori-Infected Gastric Ulcer PatientsJournal of Clinical Gastroenterology, 1995
- Prospective, randomized, investigator-blind trial ofHelicobacter pylori infection treatment in patients with refractory duodenal ulcersDigestive Diseases and Sciences, 1993